{"id":"placebo-matching-mepolizumab","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Injection site reaction"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2108429","moleculeType":"Antibody"},"_fixedAt":"2026-03-30T12:30:35.250934","_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"IL-5 is a cytokine that plays a key role in the production and survival of eosinophils, a type of white blood cell involved in allergic reactions and asthma. By inhibiting IL-5, mepolizumab reduces the number of eosinophils in the body, which can help alleviate symptoms of asthma and other eosinophilic disorders.","oneSentence":"Mepolizumab is an IL-5 inhibitor, which works by binding to the IL-5 protein and preventing it from interacting with its receptor on the surface of eosinophils, thereby reducing eosinophilic inflammation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:27:56.220Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe asthma with an eosinophilic phenotype"},{"name":"Chronic rhinosinusitis with nasal polyposis"}]},"_fixedFields":["modality→Monoclonal Antibody"],"trialDetails":[{"nctId":"NCT04157348","phase":"PHASE3","title":"Efficacy and Safety of Benralizumab in EGPA Compared to Mepolizumab.","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2019-10-29","conditions":"Eosinophilic Granulomatous Vasculitis","enrollment":140},{"nctId":"NCT05979051","phase":"PHASE2, PHASE3","title":"A Study to Evaluate the Efficacy and Safety of SHR-1703 in Subjects With Eosinophilic Granulomatosis With Polyangiitis （EGPA）","status":"RECRUITING","sponsor":"Guangdong Hengrui Pharmaceutical Co., Ltd","startDate":"2023-11-16","conditions":"Eosinophilic Granulomatosis With Polyangiitis","enrollment":166},{"nctId":"NCT05263934","phase":"PHASE3","title":"Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-07-14","conditions":"Eosinophilic Granulomatosis With Polyangiitis","enrollment":163},{"nctId":"NCT04718389","phase":"PHASE3","title":"A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-26","conditions":"Asthma","enrollment":1719},{"nctId":"NCT04133909","phase":"PHASE3","title":"Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-10-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":806},{"nctId":"NCT03562195","phase":"PHASE3","title":"A Safety and Efficacy Study of Mepolizumab in Subjects With Severe Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2018-08-29","conditions":"Asthma","enrollment":300},{"nctId":"NCT03085797","phase":"PHASE3","title":"Effect of Mepolizumab in Severe Bilateral Nasal Polyps","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-05-25","conditions":"Nasal Polyps","enrollment":414},{"nctId":"NCT03610685","phase":"PHASE4","title":"Inflammation Following Mepolizumab and Oral Corticosteroids in Asthma","status":"COMPLETED","sponsor":"NHS Greater Glasgow and Clyde","startDate":"2018-10-19","conditions":"Asthma","enrollment":33},{"nctId":"NCT03055195","phase":"PHASE2","title":"Efficacy and Safety Study of Mepolizumab in Subjects With Moderate to Severe Atopic Dermatitis","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2017-03-21","conditions":"Dermatitis, Atopic","enrollment":34},{"nctId":"NCT02836496","phase":"PHASE3","title":"Efficacy and Safety Study of Mepolizumab in Subjects With Severe Hypereosinophilic Syndrome (HES)","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-03-07","conditions":"Hypereosinophilic Syndrome","enrollment":108},{"nctId":"NCT01691521","phase":"PHASE3","title":"Efficacy and Safety Study of Mepolizumab Adjunctive Therapy in Subjects With Severe Uncontrolled Refractory Asthma","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-10-08","conditions":"Asthma","enrollment":580}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":4,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Placebo matching mepolizumab","genericName":"Placebo matching mepolizumab","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Mepolizumab is an IL-5 inhibitor, which works by binding to the IL-5 protein and preventing it from interacting with its receptor on the surface of eosinophils, thereby reducing eosinophilic inflammation. Used for Severe asthma with an eosinophilic phenotype, Chronic rhinosinusitis with nasal polyposis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}